Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew J Weickhardt

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Current Cancer Drug Targets|August 20, 2010
Strategies for overcoming inherent and acquired resistance to EGFR inhibitors by targeting downstream effectors in the RAS/PI3K pathwayAndrew J Weickhardt, Niall C Tebbutt, John M Mariadason
Annals of Palliative Medicine|September 6, 2018
Communicating prognosis of patients with advanced cancer between health care providers: a tertiary cancer center review of written correspondenceAnis A Hamid, Francis J Ha, Oindrila Das, et al.
Cancer|January 3, 2013
Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancerAndrew J Weickhardt, Dara L Aisner, Wilbur A Franklin, et al.
Critical Care and Resuscitation : Journal of the Australasian Academy of Critical Care Medicine|June 28, 2017
Survival and functional outcomes of patients with metastatic solid organ cancer admitted to the intensive care unit of a tertiary centreFrancis J Ha, Andrew J Weickhardt, Sagun Parakh, et al.
Cancer|November 22, 2013
Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinibEvelyn M Brosnan, Andrew J Weickhardt, Xian Lu, et al.
International Journal of Radiation Oncology, Biology, Physics|January 28, 2014
Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinibGregory N Gan, Andrew J Weickhardt, Benjamin Scheier, et al.
Clinical Lung Cancer|June 5, 2018
Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid TumorsD Ross Camidge, Lecia V Sequist, Pasi A Jänne, et al.
Cancer|April 11, 2012
Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancerAndrew J Weickhardt, Micol S Rothman, Smita Salian-Mehta, et al.
BMC Cancer|May 3, 2022
Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancerAndrew J Weickhardt, David K Lau, Margeaux Hodgson-Garms, et al.
Asia-Pacific Journal of Clinical Oncology|February 1, 2019
Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter studyFrancis J Ha, Lavinia Spain, Anthony Dowling, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Current Cancer Drug Targets|August 20, 2010
Strategies for overcoming inherent and acquired resistance to EGFR inhibitors by targeting downstream effectors in the RAS/PI3K pathwayAndrew J Weickhardt, Niall C Tebbutt, John M Mariadason
Annals of Palliative Medicine|September 6, 2018
Communicating prognosis of patients with advanced cancer between health care providers: a tertiary cancer center review of written correspondenceAnis A Hamid, Francis J Ha, Oindrila Das, et al.
Cancer|January 3, 2013
Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancerAndrew J Weickhardt, Dara L Aisner, Wilbur A Franklin, et al.
Critical Care and Resuscitation : Journal of the Australasian Academy of Critical Care Medicine|June 28, 2017
Survival and functional outcomes of patients with metastatic solid organ cancer admitted to the intensive care unit of a tertiary centreFrancis J Ha, Andrew J Weickhardt, Sagun Parakh, et al.
Cancer|November 22, 2013
Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinibEvelyn M Brosnan, Andrew J Weickhardt, Xian Lu, et al.
International Journal of Radiation Oncology, Biology, Physics|January 28, 2014
Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinibGregory N Gan, Andrew J Weickhardt, Benjamin Scheier, et al.
Clinical Lung Cancer|June 5, 2018
Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid TumorsD Ross Camidge, Lecia V Sequist, Pasi A Jänne, et al.
Cancer|April 11, 2012
Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancerAndrew J Weickhardt, Micol S Rothman, Smita Salian-Mehta, et al.
BMC Cancer|May 3, 2022
Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancerAndrew J Weickhardt, David K Lau, Margeaux Hodgson-Garms, et al.
Asia-Pacific Journal of Clinical Oncology|February 1, 2019
Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter studyFrancis J Ha, Lavinia Spain, Anthony Dowling, et al.
Pageof 3